Morrison R A, Fung H L
J Pharmacol Exp Ther. 1984 Oct;231(1):124-30.
The pharmacokinetics of isosorbide dinitrate (ISDN) and its isomeric mononitrate metabolites (2- and 5-ISMN) were examined in the rat. At a dose of 2 mg/kg, the oral bioavailability of ISDN was found to be about 40%. This finding corrects a previous belief that organic nitrates, when administered via the oral route, are completely metabolized by hepatic first-pass metabolism. ISDN was metabolized exclusively via its mononitrate metabolites, with the 5-ISMN being the principal product (about 90%). The ratio of 2- to 5-ISMN produced was dependent on the route of administration, being 0.18 +/- 0.03 after i.v. dosing and 0.11 +/- 0.03 after oral dosing (both mean +/- S.D.). 2-ISMN was found to decrease the plasma clearance of ISDN; this metabolite interaction occurred when drug and metabolite were administered either at the same or different intravascular sites. 5-ISMN did not affect ISDN plasma clearance when these compounds were administered at different intravascular sites. However, when 5-ISMN and ISDN were given at the same vascular site, a decrease in plasma ISDN clearance was observed. These results provide an interesting example of divergent pharmacokinetic interactions exhibited by two isomeric metabolites.
在大鼠体内研究了硝酸异山梨酯(ISDN)及其异构单硝酸酯代谢产物(2-和5-ISMN)的药代动力学。给予2mg/kg剂量时,发现ISDN的口服生物利用度约为40%。这一发现纠正了之前的一种观点,即有机硝酸盐经口服给药时会被肝脏首过代谢完全代谢。ISDN仅通过其单硝酸酯代谢产物进行代谢,其中5-ISMN是主要产物(约90%)。产生的2-ISMN与5-ISMN的比例取决于给药途径,静脉给药后为0.18±0.03,口服给药后为0.11±0.03(均为平均值±标准差)。发现2-ISMN会降低ISDN的血浆清除率;当药物和代谢产物在相同或不同的血管内部位给药时,会发生这种代谢产物相互作用。当这些化合物在不同的血管内部位给药时,5-ISMN不影响ISDN的血浆清除率。然而,当5-ISMN和ISDN在同一血管部位给药时,观察到血浆ISDN清除率降低。这些结果提供了一个有趣的例子,展示了两种异构代谢产物表现出的不同药代动力学相互作用。